fda d.i.s.c.o.: niraparib in ovarian cancer transcript
Published 6 months ago • 40 plays • Length 5:58Download video MP4
Download video MP3
Similar videos
-
5:15
fda d.i.s.c.o.: rucaparib in ovarian cancer
-
6:00
fda d.i.s.c.o.: niraparib in ovarian cancer
-
1:29
dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
-
1:29
bracanalysis cdx approved by fda for metastatic breast cancer
-
4:31
nccn guidelines and fda approvals for treating ovarian cancer
-
5:50
dana slee: ovarian cancer survivor
-
2:30
zejula capsules how to use: uses, dosage, side effects, contraindications
-
2:57
ovarian cancer: warning signs you should notice
-
2:35
clinical use of niraparib in ovarian cancer
-
0:16
copy of dr. monk on the fda approval of maintenance rucaparib in ovarian cancer
-
2:55
new parp inhibitor drug approved to treat women with recurrent ovarian cancer
-
1:58
fda approves ovarian cancer drug as treatment for advanced pancreatic cancer
-
2:46
new dangerous drug approved
-
6:57
niraparib maintenance for recurrent ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:10
dr. o'malley on fda approval of maintenance rucaparib in ovarian cancer
-
12:51
niraparib in patients with newly diagnosed advanced ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer
-
1:47
niraparib provides new hope for ovarian cancer patients
-
0:59
the evolution of parp inhibitors in ovarian cancer
-
3:10
overview of engot-ov16/nova of niraparib in ovarian cancer and why the results were not surprising